Elevance Health, Inc. 8-K

What Happened
Elevance Health, Inc. reported in an 8-K filed March 2, 2026 that on February 27, 2026 it was notified by the Centers for Medicare & Medicaid Services (CMS) of CMS’s intent to impose intermediate sanctions. The proposed sanctions would suspend enrollment of Medicare beneficiaries into the Company’s Medicare Advantage‑Prescription Drug (MA‑PD) plans and suspend certain communications to Medicare beneficiaries, effective March 31, 2026 unless CMS determines the identified issues have been satisfactorily addressed. The notice says the matters relate to alleged noncompliance with Medicare Advantage risk‑adjustment data submission requirements for service dates prior to April 3, 2023; Elevance updated its practices in April 2023 and is engaging with CMS.

Key Details

• Notice date: February 27, 2026; 8-K filed March 2, 2026.
• Proposed sanctions: intermediate sanctions suspending MA‑PD beneficiary enrollment and some communications, effective March 31, 2026 unless resolved.
• Scope: Alleged noncompliance relates to risk‑adjustment data submissions for dates of service before April 3, 2023.
• Impact: Company states the suspension would not affect benefits or plans of current MA‑PD members; Elevance revised practices in April 2023 and is working with CMS.

Why It Matters
For investors, the immediate operational impact is limited (current members’ benefits are unchanged), but a suspension of new enrollments and communications could constrain membership growth and future premium revenue if it takes effect or is prolonged. The filing indicates regulatory compliance risk tied to historical data submissions; outcomes, timing and any financial effects remain uncertain and will be material to monitor in future disclosures.